Tirzepatide emerges a groundbreaking treatment agent for individuals facing type 2 diabetes. As a dual agonist, it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide https://frasernftn266205.loginblogin.com/48691590/tirzepatide-a-novel-glp-1-and-gip-receptor-agonist